Plasma p-tau217 disagreed with amyloid PET or CSF in 8.5% — and kidney function pushed results both ways

The edition in brief

In 706 Mayo Clinic research participants with clearly positive or negative plasma p-tau217, 8.5% disagreed with amyloid PET or CSF. False negatives (5.6%) outnumbered false positives (2.8%). False negatives were linked to milder disease, higher BMI and higher eGFR; false positives to advanced disease and lower eGFR, and in unadjusted analysis to thyroid disease. The ten-year OPERA I and II extension found that starting ocrelizumab at once rather than after two years of interferon reduced 48-week confirmed disability progression (HR 0.76, 0.61–0.95) and reaching EDSS 6.0 (HR 0.57), with no rise in serious infections over the open-label years. A case-crossover study of 57,547 US adults with a first seizure found ED visits for a fall were 2.6 times as likely in the preceding week as in the same week a year earlier, and 4.5 times before first status epilepticus; the association persisted for about 22 weeks. In the MINT trial of 238 adults with generalised myasthenia gravis tapering steroids, the CD19 B-cell-depleting antibody inebilizumab reduced exacerbations including rescue therapy (HR 0.41 at 26 weeks), in both AChR- and MuSK-positive disease.